Psoriasis Drug Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028. Increasing healthcare expenditure, improvement in Psoriasis Research and Development expenditure and rising demand for newer Psoriasis medicines are major key factor which drives the Global Psoriasis Drug Market.
Psoriasis is a genetically programmed inflammatory disease caused by an overactive immune system. It causes the rapid buildup of skin cells. This buildup of cells causes scaling on the skin’s surface.It typically affects the outside of the elbows, knees or scalp, though it can appear on any location. The symptoms of Psoriasis are red patches of skin covered with thick, silvery scales, Dry & cracked skin, Thickened or pitted or ridged nails and small scaling spots. There are 7 types of Psoriasis such as Plague Psoriasis, Guttate Psoriasis, Pushtular Psoriasis, Inverse Psoriasis, erythrodermic Psoriasis and Psoriasis in children. Psoriasis is diagnosed by Physical Examination and Medical History; also Skin Biopsy is carried out. Psoriasis treatments decrease inflammation and clear the skin. Treatments are divided into three main types such as topical treatments, light therapy and systemic medications. A combination Therapy is newer treatment that is used is to combine two types of systemic drugs i.e., a traditional drug and a biologic. Biologics usually take a time to work. Combining a biologic with a faster-acting systemic drug, such as cyclosporine, is usually more effective and safe. Many doctors are prescribing combination therapies due to faster, longer-lasting results &fewer side effects, requiring lower doses, which is likely to boost Global Psoriasis Drugs Market.
Global Psoriasis Drug Market is segmented on the basis of Product, Therapy, Distribution Channel and Geography. On the Basis of Product, Global Psoriasis Drug Market is classified as TNF Inhibitors, Interleukin Blockers, Vitamin D Analogues or Combinations and Others. On the basis of Therapy Global Psoriasis Drug Market is classified into Topical Therapeutic Drugs, Systemic Therapeutic Drugs, Combinations Therapy and others. On the basis of Distribution channel Global Psoriasis Drug Market is classified into Hospital Pharmacy, Drug Stores, Online Pharmacy and Others.
The regions covered in Global Psoriasis Drug Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Most of the key players are involved in the Psoriasis Drug Market report,
By Regional & Country Analysis
North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
Growing geriatric population and prevalence of psoriasis is the most importantdriving factor of the Global Psoriasis Drug Market. The other market driving factors for the global psoriasis treatment market is growing awareness, rise in risk factors such as autoimmune diseases, diabetes etc. and greater exposure to environmental factors such as chemicals, allergens etc. As aging population increases the risk of Psoriasis and demand for Psoriasis pharmacotherapy is increases. The market will introduce the blockbuster drugs such as Vicodin and Simponi, apart from those other medications are also present in the pipeline.
The market’s constraints include lack of effective and permanent treatment and low level of awareness as to the benefits of Psoriatic pharmacotherapy has also been inhibiting growth. There is no cure for Psoriasis and most treatments are either symptomatic or temporary in nature. Other market restraints include high cost of newly launched biologics i.e., Rs 300000- Rs 600000 per annum and patent expiry of a number of blockbuster drugs such as humira, enbrel and remicade etc. Also side effects related with present medications such as hypertension, liver and kidney damage etc.
The recent market trends include vast potential reflected by novel acting biologics such as TNF inhibitors, IL-17 inhibitors etc. Therefore novel drug development especially involving biologics will be the best strategy and will lead to fast growth of the market along with less marketing expenditure. Thus product development is the critical strategy to be a market leader of Global Psoriasis Drug Market.
North America is having highest market share for Global Psoriasis Drug Market in the near future. The remarkable rise in the patient pool suffering from Psoriasis is likely to increase this regional market over the coming years. The existence of better drug manufacturers is expected to have positive impact on the North America market for Psoriasis treatment in the future.
Also Europe having a high position in the Global Psoriasis Drug market is likely to experience a decline in the demand Psoriasis treatment, following a powerful competition from biosimilars over the next few years. Latin America and Asia Pacific are projected to observe a significant growth in the Global Psoriasis Drug market over the next few years.Asia Pacific is expected to be the fastest-growing region owing to the large population and changing lifestyle habits such as smoking.Furthermore, increase in awareness through various government and NGO campaigns of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.
|Forecast Period||2022 - 2028|
|Market Size in 2020:||XX|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||XX|
|Tables, Charts & Figures:||175|
|Eli Lilly, Pfizer Inc., Janssen Biotech Inc., Celgene Corporation, Glenmark Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc)., Novartis AG, Amgen Inc., Biogen Idec, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim, Sun Pharmaceuticals Industries Ltd., Valeant Pharmaceuticals International, Inc., Biocon Limited, Cipla Ltd., Rowan Bioceuticals Private Limited, LEO Pharma, G & W Laboratories Inc., Win Medicare Pvt. Ltd., Merck and Co. Inc., Abbvie Inc. and others.|
By Product Analysis, By Therapy Analysis, By Distribution Analysis
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®